CARE™ Perspectives:

ESMO 2019

Focus on Prostate Cancer



22 Nov 2019

2018 and 2019 have seen numerous data updates and news that could affect the management of prostate cancer (PC) in Canada.

The CARE™ Genitourinary (GU) Faculty focuses on framing potentially practice changing GU updates from a Canadian perspective.

The following CARE™ Conference Report from ESMO 2019 focuses on prostate cancer updates and includes content on:

  • Metastatic castrate resistant prostate cancer (mCRPC).
  • Hormone sensitive prostate cancer (HSPC – term used interchangeably with castrate sensitive prostate cancer or CSPC).
  • Drug-drug interactions (DDIs).
  • A novel androgen receptor inhibitor for nmCRPC (non-metastatic CRPC) and mCSPC.